# How Nebius Is Turning AI Into a Medical Discovery Accelerator > On July 2, 2026, Nebius Group, listed on the Nasdaq under the ticker NBIS and based in Amsterdam, honored the most promising - Author: Maxime Marquette - Publisher: MadMax (https://mad-max.co) - Section: Analysis - Published: 2026-07-05 - Canonical URL: https://mad-max.co/en/article/comment-nebius-transforme-l-ia-en-accelerateur-de-decouvertes-medicales ## Introduction: when the **AI** **cloud** becomes a planetary laboratory ### A London ceremony that reads like a strategic signal On **July 2, 2026**, **Nebius Group**, listed on the **Nasdaq** under the ticker **NBIS** and based in **Amsterdam**, honored the most promising **startups** in health and life sciences at its **AI Discovery Awards** ceremony, held at **Town Hall by Bottaccio** in **London**. The event is not just a corporate gala: it is a precise snapshot of how fast **artificial intelligence** is reshaping global **medical** research. The program, now in its expanded version, received **647 applications**, evaluated by an independent **panel** of **28 experts** drawn from major pharmaceutical companies, academic institutions, and venture capital funds. That number alone illustrates the global appetite for the intersection of intensive **computing** and applied biology. *I see in this volume of **applications** a clear signal: the race for **medical** **AI** is no longer a niche, it has become a central axis of economic competitiveness for the West against rivals who do not share the same regulatory scruples.* ## Five categories, a sign of changing times ### From **biopharma** to connected medical devices For its **2026** edition, **Nebius** added two new categories, **Medical Devices** and **Medical Imaging**, to the three long-standing categories of **BioPharma**, **Genomics**, and **Digital Health**. This expansion reflects, according to the company, the growing role of AI in connected medical equipment and diagnostic **imaging**, where inference-heavy workloads are starting to transform clinical practice. Concretely, this means algorithms no longer just analyze **data** in a lab: they are now built directly into devices that scan, monitor, and diagnose **patients** in real time, a technical shift that would not have been conceivable just five years ago. ### Winners spanning the full digital health spectrum Among the first-place winners are **Phylo** in **biopharma**, **Corti.ai** in digital **health**, **Omniscope** in **genomics**, **Real Time Imaging Systems** in medical devices, and **Nucleo Research** in **medical** **imaging**. Each category also rewards a second and third place, with companies such as **Virgo**, **VitVio**, **Twig Bio**, **BAIBYS Fertility**, **Subtle Medical**, **Decoy Therapeutics**, **EverEx**, **DELFI Diagnostics**, **Fluent**, and **Hertility Health**. This geographic and thematic diversity is not accidental: **Nebius** also handed out regional **Trailblazer** awards, given to **Check Me** for Africa, **Hummingbird Bioscience** for Asia-Pacific, **Owkin** for Europe, the Middle East and Africa, **Arkangel AI** for Latin America, and **Xaira Therapeutics** for North America. *This global reach strikes me: medical **innovation** powered by AI is not confined to Silicon Valley or **London**, it is flowing into ecosystems that historically had limited access to research capital.* ## Money that follows ideas, not the other way around ### **Compute credits** rather than symbolic checks Nebius's choice to reward winners with **compute** and inference **credits**, rather than plain financial grants, deserves attention. Category winners receive **100,000 dollars** in **compute** and inference **credits**, runners-up **50,000 dollars**, third-place finishers **30,000 dollars**, and each regional Trailblazer winner also gets **30,000 dollars** in **compute** credits. This approach carries obvious strategic sense: for a biotech **startup**, access to massive **computing** power is often the main bottleneck, far more than traditional funding. By offering **infrastructure** directly rather than generic capital, Nebius also ensures it locks these young companies into its own **cloud** ecosystem. ### A scientific **platform** built for biomedical confidentiality Nebius used the event to preview its **Nebius Scientific AI and Healthcare Platform**, developed with teams from biotechnology, pharmaceuticals, digital health, academia, and research. This **platform** notably offers private model hosting, allowing biotech and pharmaceutical organizations to securely host their proprietary models without managing costly dedicated GPU **infrastructure**. It also features a capability called **Bring your Own Job**, designed for the custom, reproducible scientific workflows that researchers often prefer over more rigid, standardized inference endpoints. *I stay clear-eyed here: behind the philanthropic gloss of these awards, Nebius is methodically building commercial dependence on its own **cloud**, a perfectly legitimate strategy but one that should not be mistaken for pure patronage.* ## What Nebius's head of health really says ### An acceleration documented by application numbers **Dr. Ilya Burkov**, Nebius's global head of health and life sciences, summed up the stakes by explaining that the winners, and more broadly all 647 **applications** reviewed, reflect how quickly AI is transforming the pace of health research. According to him, **startups** now compress into a few months, sometimes weeks, timelines that used to take entire years. This statement, while it should be taken with the necessary distance coming from an executive who is precisely selling the **infrastructure** enabling this acceleration, nonetheless matches a trend widely documented elsewhere in the biotech industry, where AI-assisted drug discovery cycles have objectively shortened in recent years. ### A track record that already includes recognized successes The program can also point to earlier winners who have become reference names, such as **Transcripta Bio**, **Slingshot AI**, **Converge Bio**, and **Prima Mente**, which lends the initiative additional credibility beyond the organizing company's own promotional messaging. This continuity across successive editions suggests the AI Discovery Awards are not an isolated marketing stunt but a recurring mechanism for early talent identification in a sector where international competition to attract the best teams has become fierce. *I credit this continuity: a program that produces recognized winners edition after edition carries more weight than a one-off publicity operation, even if caution remains warranted about figures put forward by the company itself.* ## The geostrategic stakes behind the scientific showcase ### The West facing the global race for medical AI This initiative fits into a broader context in which major Western powers seek to preserve their lead in **artificial intelligence** applied to health, as **China** invests massively in its own computing and biomedical research capabilities, with declared ambitions of global leadership by the end of the decade. In this context, companies like Nebius, which operate globally while remaining listed on Western financial markets such as the **Nasdaq**, play a role that goes beyond simple commercial competition: they help keep a biomedical **innovation** ecosystem anchored in democratic, regulated jurisdictions. ### A computing dependency that worries **regulators** too This concentration of computing power in the hands of a few cloud providers, however, raises legitimate questions about technological sovereignty, particularly for smaller nations and **startups** that have no choice but to depend on these infrastructure giants to stay competitive in cutting-edge medical research. I note that this dependency is not unique to Nebius: it characterizes the entire cloud computing industry applied to AI, where three or four global players concentrate most of the computing capacity needed to train the most advanced models. *I believe we should applaud this **innovation** dynamic while refusing naive optimism: concentrating computing power in a few hands remains a systemic risk that Western **regulators** will one day have to confront seriously.* ## What this means for **patients**, at the end of the chain ### Faster diagnoses, a promise to verify on the ground For the ordinary patient, the promise of these innovations could translate into faster diagnoses, more precise personalized treatments, and earlier detection of complex diseases, notably thanks to advances in medical **imaging** and **genomics** driven by winners like **Nucleo Research** and **Omniscope**. It would, however, be premature to promise an immediate medical revolution: most of these startups are still in clinical and regulatory validation phases, a process that generally takes several years before a medical AI tool reaches widespread use in hospitals. ### The caution needed against technological enthusiasm I remain deliberately measured here: the recent history of AI in health is full of promising announcements that did not always live up to their claims once confronted with the real complexity of health systems, strict regulatory requirements, and biases sometimes present in the training **data** used by these models. This caution should not, however, overshadow the fact that several of these technologies, notably in diagnostic imaging, have already demonstrated measurable accuracy gains in published studies, which sets this sector apart from mere technological fads. *I admit I have no certainty about which of these twenty startups will actually change medicine a decade from now, and that is precisely why I refuse to give in to the blind enthusiasm that too often surrounds these announcements.* ## The cloud platform battle to win over biotech ### Nebius against already established American giants Nebius is not operating on virgin territory: **Amazon Web Services**, **Microsoft Azure**, and **Google Cloud** have for years courted the same biotech startups with their own compute credit and technical support programs, making competition for the best teams particularly fierce in this market segment. Nebius's strategy, which bets on explicit specialization in **health** and **life sciences** rather than a generalist offering, allows it to differentiate itself from these giants by offering more targeted support and a community of experts dedicated to the biomedical sector. ### A specialized cloud market in full expansion This commercial battle ultimately benefits the startups themselves, which gain from increased competition among providers for favorable access to computing power, an element that has become as critical as traditional funding for success in AI-assisted biomedical research. Financial analysts note that this specialized life-sciences cloud market should keep growing rapidly in the coming years, driven by rising demand for computing power to train ever more complex biomedical models. *This competition among cloud giants seems broadly healthy for innovation to me, as long as it does not lead to young companies becoming excessively dependent on a single provider that could later dictate its own terms.* ## The murky role of health **data** in this equation ### Who really owns the data training these models An issue rarely discussed publicly concerns the origin of the health data used to train these medical AI models: **patient** records, diagnostic images, genomic sequences, all highly sensitive information whose governance often remains murky once processed by third-party cloud infrastructure like Nebius's. Western regulations, notably Europe's **GDPR**, impose strict safeguards in this area, but the concrete application of these rules to fast-growing startups operating across several continents at once remains a regulatory challenge far from resolved. ### Trust that must be earned, not assumed Patients whose data feeds, directly or indirectly, these technological advances deserve greater transparency about how it is used, a standard the medical AI industry is still far from uniformly meeting despite the reassuring messaging from companies in the sector. This data governance question will likely become central in the coming years, as these technologies move from the experimental stage to large-scale clinical deployment in Western hospitals. *I refuse to look away from this blind spot: celebrating medical AI innovation without simultaneously demanding strict health data governance would be irresponsible of me as a columnist.* ## Conclusion: a bet on the future worth watching closely ### A strong signal for the **Western** medical AI ecosystem Nebius's AI Discovery Awards illustrate a real dynamic: **artificial intelligence** is gradually establishing itself as an indispensable tool for health research, with applications coming from around the world and winners spread across several continents, from Nigeria to Singapore to California. This mechanism, which combines public recognition with concrete access to computing resources, offers an interesting model for accelerating the commercialization of medical innovations, even if the organizing company obviously reaps a direct commercial benefit by locking these young companies into its infrastructure. ### See you at the next editions to judge by results The real test of this initiative will play out in the years ahead, when we can measure how many of these winners actually turned their technological promises into treatments, diagnostics, or devices approved and used at scale within Western health systems. *I close with cautious optimism: these twenty startups deserve the attention they are getting today, but only time, and real clinical results, will tell whether this enthusiasm was warranted.* **By Maxime Marquette, columnist** ## Columnist's transparency note ### Editorial stance I am not a journalist but a **columnist and analyst**. My expertise lies in observing and analysing the geopolitical, economic and strategic dynamics that shape our world. My work is to take political strategies apart, to understand global economic movements, to put the decisions of international actors in context and to offer analytical perspectives on the changes that are redefining our societies. I do not claim the cold objectivity of traditional journalism, which stops at reporting facts. **I claim analytical clarity**, rigorous interpretation and a deep understanding of the complex issues that concern us all. My role is to give meaning to the facts, to place them in their historical and strategic context, and to offer a critical reading of events. ### Method and sources This text keeps the basic distinction between **verified facts and interpretive analysis**. The rule never changes: a factual claim is published only when a verifiable source supports it, and the sources this article actually used are listed under **Sources**, never here. **Primary source families** used by the publication, when the story has them: official statements from governments and international institutions, public statements by political leaders, reports from intergovernmental organisations, dispatches from recognised international news agencies. **Secondary source families**: specialised publications, internationally recognised news media, analyses from established research institutions, reports from industry organisations. When an article cites statistical, economic or geopolitical data, it comes from the institutions that produce it (intergovernmental organisations, central banks, national statistics offices), and the exact institution is named under **Sources**. ### Nature of the analysis The analyses, interpretations and perspectives in the analytical sections of this article are a **critical, contextual synthesis** based on the information available, the trends observed and the expert comments cited in the sources consulted. My role is to interpret these facts, to set them in the context of today's geopolitical and economic dynamics, and to give them a coherent meaning within the larger story of the changes shaping our time. These analyses reflect expertise built through continuous observation of international affairs and an understanding of the strategic mechanisms that drive global actors. This article describes a documented state of affairs on its publication date, not a prediction: later developments may shift its outlook. No update is promised in advance; when an article is corrected or completed, the change is dated in the text. ## Sources ### Primary sources - Nebius, official AI Discovery Awards page, criteria and panel — accessed July 2026 - Business Insider / Nebius Group press release, full details on winners and amounts — July 2, 2026 ### Secondary sources - LinkedIn Nebius, photos and recap of the London ceremony — July 2026 - Finanzwire, coverage of the press release on awarded health innovations — July 2026 - Nebius Group, corporate site, Nasdaq NBIS listing and Amsterdam headquarters — accessed July 2026 - SEC, Nebius Group's annual Form 20-F report filing for the fiscal year ended December 31, 2025 — April 30, 2026 --- Source: Maxime Marquette, MadMax. When citing, name the author and link https://mad-max.co/en/article/comment-nebius-transforme-l-ia-en-accelerateur-de-decouvertes-medicales